Ngal as a novel target for the treatment of chronic kidney disease

The severity of renal lesions after nephron reduction varied substantially among mouse strains and required activation of EGFR. Lipocalin 2 (Lcn2, also known as neutrophil gelatinase–associated lipocalin [NGAL]), the most highly upregulated gene in a mouse strain which develop severe renal lesions, is not simply a marker of renal lesions, but also an active player in disease progression. The severity of renal lesions was dramatically reduced in Lcn2–/– mice. Lcn2 expression increases upon EGFR activation and Lcn2 mediates its mitogenic effect during renal deterioration. EGFR inhibition prevented Lcn2 upregulation and lesion development in mice expressing a dominant negative EGFR isoform. Cell proliferation was dramatically reduced in Lcn2–/–mice. LCN2 is increased particularly in patients who rapidly progressed to end-stage renal failure. (Viau A. et al., J Clin Invest. 2010 Nov;120(11):4065-76. doi: 10.1172/JCI42004.)

Keywords: Nephrology, Diagnostics, Biomarker, Chronic Kidne
Patent Application number: EP10306077.8
Inventors:
Martine BURTINKhalil EL KAROUIFabiola TERZIAmandine VIAUClément NGUYEN
Publications:
Viau et al 2010 The Journal of Clinical Investiga

Reference:

BIO10870-T1

Business Developper
contact
Aymeric Empereur
Aymeric Empereur
Business Developer
Patent filling date: 2010-10-01

You might also be interested in